Literature DB >> 14623642

Beta-cell regeneration in a patient with type 1 diabetes mellitus who was receiving immunosuppressive therapy.

Akio Kuroda, Yoshimitsu Yamasaki, Akihisa Imagawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14623642     DOI： 10.7326/0003-4819-139-10-200311180-00030-w1

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  4 in total

1.  Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating.

Authors:  S Perl; J A Kushner; B A Buchholz; A K Meeker; G M Stein; M Hsieh; M Kirby; S Pechhold; E H Liu; D M Harlan; J F Tisdale
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

2.  Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft.

Authors:  E H Liu; B J Digon; B Hirshberg; R Chang; B J Wood; Z Neeman; A Kam; R A Wesley; S M Polly; R M Hofmann; K I Rother; D M Harlan
Journal:  Diabetologia       Date:  2009-05-06       Impact factor: 10.122

3.  Beta cell function during rapamycin monotherapy in long-term type 1 diabetes.

Authors:  L Piemonti; P Maffi; L Monti; V Lampasona; G Perseghin; P Magistretti; A Secchi; E Bonifacio
Journal:  Diabetologia       Date:  2010-11-03       Impact factor: 10.122

4.  Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.

Authors:  Kristina I Rother; Lisa M Spain; Robert A Wesley; Benigno J Digon; Alain Baron; Kim Chen; Patric Nelson; H-Michael Dosch; Jerry P Palmer; Barbara Brooks-Worrell; Michael Ring; David M Harlan
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.